Open Access Protocol Multicentre randomised placebo controlled trial extract Japanese herbal medicine Daikenchuto prevent bowel dysfunction adult liver transplantation DKB 14 Study Toshimi Kaido1 Tsuyoshi Shimamura2 Yasuhiko Sugawara3 Hiroshi Sadamori4 Ken Shirabe5 Michio Yamamoto6 Shinji Uemoto1 To cite Kaido T Shimamura T Sugawara Y et al Multicentre randomised placebo controlled trial extract Japanese herbal medicine Daikenchuto prevent bowel dysfunction adult liver transplantation DKB 14 Study BMJ Open 20155 e008356 doi101136 bmjopen2015008356 Prepublication history paper available online To view files visit journal online httpdxdoiorg101136 bmjopen2015008356 Received 31 March 2015 Revised 26 June 2015 Accepted 7 August 2015 ABSTRACT Introduction This multicentre randomised controlled clinical trial aim determine ability extract TJ100 Daikenchuto traditional Japanese herbal medicine Kampo prevent bowel dysfunction 110 patients liver transplantation LT Methods analysis The following coprimary end points evaluated postoperative day 7 total oral enteral caloric intake abdominal distension abdominal pain The secondary end points comprise sequential changes total oral enteral caloric intake LT sequential changes numeric rating scales abdominal distension pain elapsed time postoperative passage stool quality life assessment Gastrointestinal Symptom Rating Scale score Japanese version postoperative liver function liver regeneration rate incidence bacteraemia bacterial strain trough level immunosuppressants occurrence acute cellular rejection discharge 2 months LT sequential changes portal venous flow graft ascites discharge The arms study comprise 55 patients arm Ethics dissemination The study conducted according CONSORT statement All participants signed written consent form study approved institutional review board participating institute conducted accordance Declaration Helsinki 1996 The findings disseminated scientific professional conferences peerreviewed journals Trial registration number The DKB 14 Study registered University Hospital Medical Information Network Clinical Trial Registration UMIN CTR Japan registration number UMIN000014326 2014 For numbered affiliations end article Correspondence Professor Toshimi Kaido kaidokuhpkyotouacjp INTRODUCTION Liver transplantation LT patients end extensive surgeries stage liver diseases including liver cirrhosis hepatocellular carcinoma acute liver failure Moreover proteinenergy malnutri tion common patients endstage liver disease requiring LT closely asso ciated posttransplant risk morbidity mortality13 Such patients usually accompanied bowel dysfunction LT long surgical durations wide incisions prevents early abdominal postoperative food intake orally enteral tube subsequently leads worsening malnutrition The enhanced recovery surgery ERAS protocol recently intro duced types surgery including organ transplantation47 Postoperative man agement recommended ERAS proto includes early initiation normal col food intake enteral feeding gastro intestinal tube feeding indicated patients early oral nutrition initiated obvious undernutrition time surgery However normal food intake enteral feeding started patient bowel dysfunction surgery Moreover 24 h early traditional Daikenchuto Japanese herbal medicine Kampo fre quently prescribed prevent treat post operative ileus Japan8 9 The powdered extract Daikenchuto TJ100 Tsumura Co Tokyo Japan available aqueous extract containing 22 Japanese pepper 56 processed ginger 33 ginseng 889 powdered maltose syrup A recent multicentre phase III trial JFMC401001 TJ100 signiﬁcantly reduced elapsed time ﬁrst bowel movement compared placebo hepatic Kaido T et al BMJ Open 20155e008356 doi101136bmjopen2015008356 1 Open Access resection10 However ability TJ100 normalise bowel paralysis LT effects early total caloric intake delivered orally enterally surgery key element ERAS protocol prospectively investigated Therefore designed mul ticentre randomised doubleblind placebocontrolled trial determine enhancement effects TJ100 oral enteral caloric intake ability prevent postoperative paralytic ileus patients undergoing living donor LT LDLT deceased donor LT DDLT METHODS AND ANALYSIS Objective Postoperative early oral enteral intake crucial element ERAS protocol The DKB 14 Study multicentre randomised doubleblind placebocontrolled trial aims determine enhancement effect TJ100 oral enteral caloric intake ability prevent postoperative paralytic ileus patients LDLT DDLT Resources A research grant Tsumura Co Tokyo Japan End points The following primary end points evaluated postoperative day POD 7 Total oral enteral caloric intake Abdominal distension determined numeric rating scales NRS Abdominal pain determined NRS The following secondary end points evaluated Chronological changes total oral enteral caloric intake POD 3 5 7 10 14 Chronological changes NRS POD 5 7 10 14 Elapsed time extubation ﬁrst post operative defaecation Quality life assessment Gastrointestinal Symptom Rating Scale score Japanese V12 POD 7 14 Liver function determined measuring total protein albumin total bilirubin direct bilirubin aspartate aminotransferase alanine aminotransferase γglutamyl transpeptidase choline esterase POD 3 5 7 10 14 Liver regeneration rates determined CT calcu lated postoperative liver volumegraft liver weight time LT POD 14 21 graft volume patients underwent LT The incidence bacteraemia POD 14 bac terial strain Trough levels immunosuppressants POD 3 5 7 10 14 The incidence acute cellular rejection POD 14 2 Discharge 2 months LT Flow speed volume portal vein POD 3 5 7 10 14 Ascites volume mLday abdominal drain POD 3 5 7 10 14 Eligibility criteria Inclusion Patients endstage liver disease sched uled undergo LT Age 20 years time registration Satisﬁes indication criteria LT partici pating institution Written informed consent provided participate study Exclusion Uncontrollable active infection liver Uncontrollable malignant diseases hepato cellular carcinoma Clinically problematic dysfunction organs Likely severe intraabdominal adhesion history surgeries past history mechanical ileus Medication antipsychotic antidepressant gastrointestinal prokinetic drugs Patients Kampo medicines Women pregnant lactating Any medical condition render patient unsuitable inclusion according opinion investigator institution Registration An eligibility report form delivered regis tration centre Institute Advancement Clinical Translational Science Kyoto University Hospital Eligible patients centrally randomised Arm A TJ100 Arm B placebo accord ance minimisation method assigning patients Arm A Arm B according type LT LDLT DDLT body weight 60 60 age 50 50 years institution variables LT Information required followup evaluations sent registration centre Institute Advancement Clinical Translational Science The randomisation list known advance investigators The statistical analysis prepar ation tables graphs report study statistician study blinded extent possible The unblinding place data entered database study requests closed database frozen Data Manager study Treatment methods Arm A TJ100 group TJ100 5 g solution administered orally enterally tube times day Kaido T et al BMJ Open 20155e008356 doi101136bmjopen2015008356 immediately meals 8 h 14 consecutive days POD 1 14 Arm B placebo group Placebo 5 g solution administered orally enterally tube times day immedi ately meals 8 h 14 consecutive days POD 1 14 TJ100 matching placebo manufactured Tsumura Co Tokyo Japan We monitor adherence hearing patient checking number trial drugs TJ100 placebo administered Prohibited permitted drugs Prohibited drugs drugs known promote bowel movement prohibited protocol treatment erythromycin acetylcholine chloride itopride hydrochloride mosapride citrate aclatonium napadisi late neostigmine methylsulfate pantethine panthenol prostaglandin F2α prosultiamine fursultiamine trime butine maleate amidotrizoate sodium meglumine Permitted drugs metoclopramide domperidone treat postoperative nauseavomiting immunosup pressants steroid including tacrolimus cyclosporine azathioprine mizoribin mycophenolate mofetil Criteria discontinuing protocol treatment Grade 3 postoperative diarrhoea clinical adverse effects CTCAE V40 criteria Data collection Prospective data patients including medical history physical ﬁndings laboratory ﬁndings perioperative clinical information complications collected Study design statistical analysis The primary end points statistically evaluated POD 7 total oral enteral caloric intake abdominal distension abdominal pain determined NRS The multiplicity issue inﬂation type I error analysis end points addressed ﬁxedsequence testing method The order tests ﬁxed controls familywise error rate The testing procedure start hypothesis total oral enteral caloric intake followed NRS abdominal distension NRS abdominal symptoms order Each test proceed previously tested hypotheses rejected Each hypothesis tested 5 signiﬁcance level The sample size calculated basis previous ﬁnding mean value total oral enteral caloric intake POD 7 administration TJ100 1000 kcal day SD850 unpublished data We speculated patients administered TJ100 intake 500 kcalday adminis tered TJ100 Thus assuming arms Open Access Arm B 062 SD sample size calculated basis t test twosided signiﬁcance level 5 power 80 resulted requirement 47 patients group Taking 15 exclusion analysis account number patients accrued set 55 treatment arm 110 total If sample analyses 47 group sided signiﬁcance level 5 probability event value NRS Arm A larger Wilcoxon ranksum test approximate power 80 NRS test abdominal distension abdominal symptoms The ﬁrst primary end point total oral enteral caloric intake POD 7 compared treatment groups t test The second primary end points values NRS abdominal distension abdom inal pain compared treatment groups Wilcoxon ranksum test When total oral caloric enteral intake data POD 7 50 patients collected conduct interim ana lysis conﬁrm distribution total oral enteral caloric intake POD 7 doubleblind conditions If distribution obviously deviates normal distribution Wilcoxon ranksum test primary analysis total oral enteral caloric intake POD 7 Participating institutions Fourteen leading Japanese institutions perform LT participate trial Registration protocol The protocol approved institutional review board participating institute conducted accordance Declaration Helsinki 1996 Written informed consent obtained patients enrolment randomisation investi registered gators The DKB 14 Study University Hospital Medical Information Network Clinical Trial Registration UMINCTR Japan registra tion number UMIN000014326 2014 Study status This study currently collecting data publication concerning analysis data collected date Author affiliations 1Division HepatoBiliaryPancreatic Transplant Surgery Department Surgery Graduate School Medicine Kyoto University Kyoto Japan 2Division Organ Transplantation Hokkaido University Hospital Sapporo Japan 3Artificial Organ Transplantation Division Department Surgery Graduate School Medicine The University Tokyo Tokyo Japan 4Department Gastroenterological Surgery Okayama University Graduate School Medicine Dentistry Pharmaceutical Sciences Okayama Japan 5Department Surgery Science Graduate School Medical Sciences Kyushu University Fukuoka Japan Kaido T et al BMJ Open 20155e008356 doi101136bmjopen2015008356 3 Open Access 6Institute Advancement Clinical Translational Science Kyoto University Hospital Kyoto Japan Contributors TK SU conceived study All authors involved development study protocol TK prepared draft manuscript authors critically reviewed revised approved subsequent final version Funding This work supported research grant Tsumura Co Tokyo Japan Competing interests None declared Ethics approval The protocol approved institutional review board participating hospital Patient consent Obtained Provenance peer review Not commissioned externally peer reviewed Open Access This Open Access article distributed accordance Creative Commons Attribution Non Commercial CC BYNC 40 license permits distribute remix adapt build work non commercially license derivative works different terms provided original work properly cited use noncommercial See http creativecommonsorglicensesbync40 REFERENCES 1 Selberg O Böttcher J Tusch G et al Identification highand lowrisk patients liver transplantation prospective cohort study nutritional metabolic parameters 150 patients Hepatology 19972562557 2 Sanchez AJ ArandaMichel J Nutrition liver transplant patient Liver Transplant 200612131016 3 Stickel F Inderbitzin D Candinas D Role nutrition liver transplantation endstage chronic liver disease Nutr Rev 2008664754 4 Weimann A Braga M Harsanyi L et al ESPEN Guidelines 5 Enteral Nutrition Surgery including organ transplantation Clin Nutr 20062522444 Lassen K Coolsen MM Slim K et al ERAS Society European Society Clinical Nutrition Metabolism International Association Surgical Metabolism Nutrition Guidelines perioperative care pancreaticoduodenectomy Enhanced Recovery After Surgery ERAS Society recommendations Clin Nutr 20123181730 6 Gustafsson UO Scott MJ Schwenk W et al Enhanced Recovery After Surgery Society Guidelines perioperative care elective colonic surgery Enhanced Recovery After Surgery ERAS Society recommendations Clin Nutr 201231783800 7 Mortensen K Nilsson M Slim K et al Enhanced Recovery After Surgery ERAS Group Consensus guidelines enhanced recovery gastrectomy Enhanced Recovery After Surgery ERAS Society recommendations Br J Surg 2014101120929 8 Endo S Nishida T Nishikawa K et al Daikenchuto Chinese herbal medicine improves stasis patients total gastrectomy jejunal pouch interposition Am J Surg 2006192 913 Iwai N Kume Y Kimura O et al Effects herbal medicine DaiKenchuto anorectal function children severe constipation Eur J Pediatr Surg 20071711518 9 10 Shimada M Morine Y Nagano H et al Effect TU100 traditional Japanese medicine administered hepatic resection patients liver cancer multicenter phase III trial JFMC401001 Int J Clin Oncol 20152095104 4 Kaido T et al BMJ Open 20155e008356 doi101136bmjopen2015008356